The thrombolytic effect of miniplasmin in a canine model of femoral artery thrombosis

Thrombosis Research

Volumn 122, Issue 5, 2008, Pages 683-690

  Fu, Jieying ^a,b   Ren, Jianping ^a   Zou, Libo ^b   Bian, Guangxing ^a   Li, Ruifu ^a   Lu, Qiujun ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Femoral artery thrombosis; Hemorrhage; Miniplasmin; Recombinant tissue plasminogen activator; Thrombolytic therapy

Indexed keywords

ALTEPLASE; D DIMER; FIBRINOGEN; MINIPLASMIN; PLASMINOGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMORAL ARTERY FLOW; FEMORAL ARTERY THROMBOSIS; FIBRINOLYSIS; HEMODYNAMIC PARAMETERS; INCIDENCE; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBUS;

ANIMALS; BLOOD COAGULATION; BLOOD FLOW VELOCITY; DISEASE MODELS, ANIMAL; DOGS; FEMORAL ARTERY; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; MALE; PEPTIDE FRAGMENTS; PLASMIN; THROMBOLYTIC THERAPY; THROMBOSIS;

EID: 49549104686     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.01.007     Document Type: Article

References (25)

1. Franzosi M.G., Santoro E., De Vita C., Geraci E., Lotto A., Maggioni A.P., et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto-1 study. The GISSI Investigators. Circulation 98 (1998) 2659-2665
2. Wilcox R.G., von der Lippe G., Olsson C.G., Jensen G., Skene A.M., and Hampto J.R. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis. Lancet 335 (1990) 1175-1178
3. Ouriel K., Shortell C.K., DeWeese J.A., Green R.M., Francis C.W., Azodo M.V.U., et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 19 (1994) 1021-1030
4. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators. N Engl J Med 329 (1993) 673-682
5. Gore J.M., Stoan M., Price T.R., Randall A.M., Bovill E., Collen D., et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 83 (1991) 448-459
6. Kanter D.S., Mikkola K.M., Patel S.R., Parker J.A., and Goldhaber S.Z. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 111 (1997) 1241-1245
7. Ouriel K., Gray B., Clair D.G., and Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 11 (2000) 295-298
8. Ouriel K., Veith F.J., and Sasahara A.A. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery Investigators. N Engl J Med 338 (1998) 1105-1111
9. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 354 (1999) 716-722
10. Medynski D., Tuan M., Liu W., Wu S., and Lin X. Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies. Protein Expr Purif 52 (2007) 395-402
11. Nagai N., Demarsin E., Vanhoef B., Wouters S., Cingolani D., Laroche Y., et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 1 (2003) 307-313
12. 2-Macroglobulin is the primary inhibitor of miniplasmin in vitro and in vivo in the mouse. Biochem J 255 (1988) 725-730
13. Kageyama S., Yamamoto H., Nakazawa H., and Yoshimoto R. Anti-human vWF monoclonal antibody, AjvW-2 Fab, inhibits-repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 101 (2001) 395-404
14. Eobello S.S., Blank H.S., and Lucchesi B.R. Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis. Thromb Res 98 (2000) 531-540
15. Tillet W.S., Johnson A.J., and McCarthy W.R. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J Clin Invest 34 (1955) 169-185
16. Ouriel K. Current status of thrombolysis for peripheral arterial occlusive disease. Ann Vasc Surg 16 6 (2002) 797-804
17. Hilger T., Niessen F., Diedenhofen M., Hossmann K.A., and Hoehn M. Magnetic resonance angiography of thromboembolic stroke in rats: indicator of recanalization probability and tissue survival after recombinant tissue plasminogen activator treatment. J Cereb Blood Flow Metab 22 (2002) 652-662
18. Niessen F., Hilger T., Hoehn M., and Hossmann K.A. Thrombolytic treatment of clot embolism in rat: comparison of intra-arterial and intravenous application of recombinant tissue plasminogen activator. Stroke 33 (2002) 2999-3005
19. Lee S.R., Tsuji K., and Lo E.H. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24 (2004) 671-678
20. Pfefferkorn T., and Rosenberg G.A. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34 (2003) 2025-2030
21. Forsberg E., and Kjellen L. Heparan sulfate: lessons from knockout mice. J Clin Invest 108 (2001) 175-180
22. Wang X., Lee S.R., Arai K., Tsuji K., Rebeck G.W., and Lo E.H. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9 (2003) 1313-1317
23. Marder V.J., Landskroner K., Novokhatny V., Zimmerman T., Koig M., and Kanouse J.J. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 86 (2001) 739-745
24. Ajjan R., and Grant P.J. Coagulation and atherothrombotic disease. Atherosclerosis 186 (2006) 240-259
25. Senior K. Thrombolysis without bleeding. DDT 6 (2001) 1246-1248